11/04/2021 | Press release | Distributed by Public on 11/04/2021 14:51
☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
26-1679911
|
|
(State or other jurisdiction of
incorporation or organization) |
(I.R.S. Employer
Identification No.) |
|
333 Oyster Point Boulevard
South San Francisco, CA
|
94080
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Title of Each Class of Securities Registered
|
Trading
Symbol
|
Name of Each Exchange
on which Securities are Registered
|
||
Common Stock, par value $0.001 per share
|
NGM
|
The Nasdaq Stock Market LLC
|
Large Accelerated Filer | ☐ | Accelerated filer | ☒ | |||
Non-accelerated filer | ☐ | Smaller reporting company | ☐ | |||
Emerging growth company |
☒
|
Incorporated by Reference
|
|||||||||||||
Exhibit
Number |
Description
|
Schedule
Form |
File
Number |
Exhibit
|
Filing
Date |
||||||||
31.1
|
Certification of Principal Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
||||||||||||
31.2
|
Certification of Principal Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
||||||||||||
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
NGM BIOPHARMACEUTICALS, INC.
|
||||||
Date: November 4, 2021 | By: |
/s/ David J. Woodhouse
|
||||
David J. Woodhouse
|
||||||
Chief Executive Officer and Director
|
||||||
(Principal Executive Officer)
|
||||||
Date: November 4, 2021 | By: |
/s/ Siobhan Nolan Mangini
|
||||
Siobhan Nolan Mangini
|
||||||
Chief Financial Officer
|
||||||
(Principal Financial Officer)
|